Kane Biotech Inc.
KNBIF
$0.03
$0.006.40%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 403.70K | 1.34M | 1.77M | 1.52M | 1.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 403.70K | 1.34M | 1.77M | 1.52M | 1.47M |
| Cost of Revenue | 473.10K | 994.00K | 1.13M | 881.80K | 746.90K |
| Gross Profit | -69.30K | 344.10K | 640.50K | 640.60K | 728.10K |
| SG&A Expenses | 1.27M | 1.71M | 2.33M | 2.26M | 2.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.39M | 3.38M | 4.42M | 4.24M | 4.53M |
| Operating Income | -1.99M | -2.04M | -2.65M | -2.72M | -3.06M |
| Income Before Tax | -2.32M | -2.37M | -3.01M | -3.27M | -3.61M |
| Income Tax Expenses | -936.00K | -936.00K | -936.00K | -936.00K | -- |
| Earnings from Continuing Operations | -1.38 | -1.44 | -2.07 | -2.33 | -3.61 |
| Earnings from Discontinued Operations | -936.00K | -882.60K | 6.73M | 6.80M | 7.70M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.32M | -2.32M | 4.66M | 4.47M | 4.08M |
| EBIT | -1.99M | -2.04M | -2.65M | -2.72M | -3.06M |
| EBITDA | -1.85M | -1.94M | -2.54M | -2.58M | -2.93M |
| EPS Basic | -0.01 | -0.02 | 0.04 | 0.03 | 0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.01 | -0.02 | 0.02 | 0.02 | 0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 789.86M | 594.32M | 563.65M | 545.44M | 539.72M |
| Average Diluted Shares Outstanding | 807.35M | 611.81M | 589.31M | 571.10M | 565.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |